Last reviewed · How we verify
Atomoxetine (ATO)
Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses.
Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses. Used for Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults, ADHD-related symptoms in patients with comorbid conditions.
At a glance
| Generic name | Atomoxetine (ATO) |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Norepinephrine reuptake inhibitor (NRI) |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine from the synaptic cleft. This increases norepinephrine concentration in key brain regions involved in attention and executive function. Unlike stimulant medications, it does not directly release norepinephrine or dopamine and has minimal abuse potential.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults
- ADHD-related symptoms in patients with comorbid conditions
Common side effects
- Decreased appetite
- Nausea
- Dizziness
- Fatigue
- Insomnia
- Headache
- Abdominal pain
- Mood swings / irritability
- Increased blood pressure
- Increased heart rate
Key clinical trials
- Endotype DIrected Treatment for OSA in Down Syndrome (PHASE4)
- Medications for Obstructive Sleep Apnea In Children With Down Syndrome (PHASE2)
- A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
- Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atomoxetine (ATO) CI brief — competitive landscape report
- Atomoxetine (ATO) updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI